Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Ju, Andrew W ^a   Wang, Hongkun ^b   Oermann, Eric K ^a   Sherer, Benjamin A ^c   Uhm, Sunghae ^a   Chen, Viola J ^a   Pendharkar, Arjun V ^c   Hanscom, Heather N ^a   Kim, Joy S ^a   Lei, Siyuan ^a   Suy, Simeng ^a   Lynch, John H ^c   Dritschilo, Anatoly ^a   Collins, Sean P ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

CyberKnife; Hypofractionation; Intermediate risk; Monotherapy; Prostate cancer; SBRT; Stereotactic body radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CYBERKNIFE; DOSIMETRY; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD REVIEW; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE; WHOLE BODY RADIATION;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOSURGERY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84873041892     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-30     Document Type: Article

References (47)

1. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012, 82:e17-e24. 10.1016/j.ijrobp.2010.10.075, 21324610.
2. Ritter M, Forman J, Kupelian P, Lawton C, Petereit D. Hypofractionation for prostate cancer. Cancer J 2009, 15:1-6. 10.1097/PPO.0b013e3181976614, 3039916, 19197165.
3. Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, Benassi M, Strigari L. Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2011, 79:1013-1021. 10.1016/j.ijrobp.2009.12.045, 20447774.
4. Collins SP, McRae D, Gagnon G, Dritschilo A. New directions in radiation therapy in prostate cancer, In: Pestell, Richard G., Nevalainen, Marja T. editors. Prostate cancer: signaling networks, genetics, and new treatment strategies 2008, 323-338. Totowa, NJ: Humana Press.
5. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDRSM CyberKnife Treatment for Localized Prostatic Carcinoma: Dosimetry Comparison With HDR Brachytherapy and Preliminary Clinical Observations. Int J Radiat Oncol Biol Phys 2008, 70:1588-1597. 10.1016/j.ijrobp.2007.11.067, 18374232.
6. Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach Iii M, Ma L. Dose Gradient Near Target-Normal Structure Interface for Nonisocentric CyberKnife and Isocentric Intensity-Modulated Body Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2010, 78:58-63. 10.1016/j.ijrobp.2009.07.1752, 20133073.
7. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional Motion of the Prostate During Hypofractionated Radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:236-246. 10.1016/j.ijrobp.2008.04.051, 2725181, 18722274.
8. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic Body Radiotherapy as Boost for Organ-confined Prostate Cancer. Technol Cancer Res T 2010, 9:575-582.
9. Oermann EK, Slack RS, Hanscom HN, Lei S, Suy S, Park HU, Kim JS, Sherer BA, Collins BT, Satinsky AN, et al. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer. Technol Cancer Res Treat 2010, 9:453-462.
10. Corner C, Rojas AM, Bryant L, Ostler P, Hoskin P. A Phase II Study of High-Dose-Rate Afterloading Brachytherapy as Monotherapy for the Treatment of Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2008, 72:441-446. 10.1016/j.ijrobp.2007.12.026, 18249501.
11. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, Gustafson G. High-Dose-Rate Monotherapy: Safe and Effective Brachytherapy for Patients With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2011, 81:1286-1292. 10.1016/j.ijrobp.2010.10.015, 21310546.
12. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004, 171:1098-1104. 10.1097/01.ju.0000113299.34404.22, 14767279.
13. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High-dose-rate prostate brachytherapy an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol-Canc 2010, 33:481-488.
14. Rogers CL, Alder SC, Rogers RL, Hopkins SA, Platt ML, Childs LC, Crouch RH, Hansen RS, Hayes JK. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012, 187:109-116. 10.1016/j.juro.2011.09.050, 22088340.
15. Yoshioka Y, Konishi K, Sumida I, Takahashi Y, Isohashi F, Ogata T, Koizumi M, Yamazaki H, Nonomura N, Okuyama A, Inoue T. Monotherapeutic High-Dose-Rate Brachytherapy for Prostate Cancer: Five-Year Results of an Extreme Hypofractionation Regimen With 54 Gy in Nine Fractions. Int J Radiat Oncol Biol Phys 2011, 80:469-475. 10.1016/j.ijrobp.2010.02.013, 20646858.
16. Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010, 9:473-477.
17. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3. 10.1186/1748-717X-6-3, 3022740, 21219625.
18. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009, 8:387-392.
19. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma LJ, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and Psa response. Int J Radiat Oncol 2012, 82:228-234.
20. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1. 10.1186/1471-2490-10-1, 2831888, 20122161.
21. King CR, Brooks JD, Gill H, Presti JC. Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2012, 82:877-882. 10.1016/j.ijrobp.2010.11.054, 21300474.
22. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, Collins SP, Kaplan ID. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012, 118:3681-3690. 10.1002/cncr.26699, 22170628.
23. Townsend NC, Huth BJ, Ding W, Garber B, Mooreville M, Arrigo S, Lamond J, Brady LW. Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol 2011, 34:6-10. 10.1097/COC.0b013e3181c4c7c4, 20065849.
24. Lee YH, Son SH, Yoon SC, Yu M, Choi BO, Kim YS, Jang HS, Lee SN, Jang JS, Hwang TK. Stereotactic body radiotherapy for prostate cancer: A preliminary report. Asia Pac J Clin Oncol 2012,
25. Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, Kernen KM, Hollander JB, Gonzalez JA, Martinez AA, et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: Should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 2006, 65:999-1007. 10.1016/j.ijrobp.2006.02.039, 16750320.
26. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, et al. Prostate Cancer version 3.2012. NCCN Clinical Practice Guidelines in Oncology 2012, 6.
27. Lei S, Piel N, Oermann EK, Chen V, Ju AW, Dahal KN, Hanscom HN, Kim JS, Yu X, Zhang G, et al. Six-dimensional correction of intra-fractional prostate motion with cyberknife stereotactic body radiation therapy. Front Oncol 2011, 1:48. 3356099, 22655248.
28. Oermann EK, Suy S, Hanscom HN, Kim JS, Lei S, Yu X, Zhang G, Ennis B, Rohan JP, Piel N, et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol 2011, 4:12. 10.1186/1756-8722-4-12, 3083385, 21439088.
29. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care 1995, 33:AS145-155.
30. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905. 10.1016/S0090-4295(00)00858-X, 11113727.
31. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233. 10.1097/00005650-199603000-00003, 8628042.
32. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol 2006, 65:965-974.
33. Choi S, Wallner KE, Merrick GS, Cavanagh W, Butler WM. Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J 2004, 10:175-180. 10.1097/00130404-200405000-00007, 15285927.
34. Merrick GS, Butler WM, Wallner KE, Burden LR, Dougherty JE. Extracapsular radiation dose distribution after permanent prostate brachytherapy. Am J Clin Oncol 2003, 26:e178-189. 10.1097/01.coc.0000091297.21810.fa, 14528094.
35. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999, 17:1155.
36. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003, 41:582-592.
37. Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G. PSA Kinetics and PSA Bounce Following Permanent Seed Prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2007, 69:426-433. 10.1016/j.ijrobp.2007.03.031, 17869662.
38. Butzbach D, Waterman FM, Dicker AP. Can extraprostatic extension be treated by prostate brachytherapy? An analysis based on postimplant dosimetry. Int J Radiat Oncol Biol Phys 2001, 51:1196-1199. 10.1016/S0360-3016(01)02652-9, 11728677.
39. Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, Bostwick DG. The radial distance of extraprostatic extension of prostate carcinoma. Cancer 1999, 85:2630-2637. 10.1002/(SICI)1097-0142(19990615)85:12<2630::AID-CNCR20>3.0.CO;2-L, 10375112.
40. Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology 2000, 55:382-386. 10.1016/S0090-4295(99)00458-6, 10699615.
41. Teh BS, Bastasch MD, Wheeler TM, Mai W-Y, Frolov A, Uhl BM, Lu HH, Carpenter LS, Chiu JK, McGary J, et al. IMRT for prostate cancer: Defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys 2003, 56:184-191. 10.1016/S0360-3016(03)00085-3, 12694837.
42. Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 2007, 109:41-47. 10.1002/cncr.22341, 1892752, 17133416.
43. Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 2006, 68:1257-1262. 10.1016/j.urology.2006.08.1056, 17141830.
44. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74. 10.1016/j.ijrobp.2007.06.054, 17765406.
45. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261. 10.1056/NEJMoa074311, 18354103.
46. Simone NL, Menard C, Soule BP, Albert PS, Guion P, Smith S, Godette D, Crouse NS, Sciuto LC, Cooley-Zgela T, et al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. Int J Radiat Oncol Biol Phys 2008, 70:90-95. 10.1016/j.ijrobp.2007.05.057, 2267374, 17855015.
47. Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2010, 78:442-448. 10.1016/j.ijrobp.2009.07.1748, 20137864.